Dennis Huang

Chief Technical Operations Officer & EVP Gene Therapy Operations | Ultragenyx

About Dennis

Mr. Huang joined Ultragenyx in May 2015 and is responsible for leading the technical and pharmaceutical development, manufacturing and supply chain functions covering broad technical modalities like small molecules, recombinant proteins, nucleic acid medicines and AAV gene therapy. This includes product approvals and launches for Mepsevii ®, Crysvita® and Dojolvi®. In addition Mr. Huang is the executive team member responsible for the Gene Therapy Platform strategy, research, product development, manufacturing and supply chain. 

Prior to joining Ultragenyx, Mr. Huang was Senior Vice President of Manufacturing and Supply Chain for InterMune Inc., where he led the global manufacturing and supply chain organization for the company which led to the US approval of Esbriet ®. Prior to InterMune, he served as Vice President of Biologics Manufacturing and Development for Allergan, Inc. where he held dual responsibilities in R&D and Global Technical Operations. Earlier in his career, Mr. Huang held leadership positions at Novartis AG (formerly Chiron, Inc), Genentech, Inc., and Synergen (currently Amgen), where he worked in various roles including manufacturing, quality and process and analytical development. 

Mr. Huang serves on the Board of Directors of two privately-held biotechnology companies; CytoDel and Ornovi. 

Mr. Huang earned a B.A. in chemistry from Knox College.  

See all Board Members